The CCS consists of sinoatrial node (SAN), atrioventricular node (AVN), and peripheral components of the fast conducting His-Purkinje fibers. CCS formation is a complex process that involves multiple cell types. During mouse development, the first heartbeat is recorded in the inflow tract as early as E8.0 1,2 and, later, the sinus venosus of the forming heart tube functions as a primitive pacemaker region. The first morphologically discernable SAN is formed at E11.5, which becomes further mature and fully functional at E13.5. 3,4 A subset of atrioventricular canal tissue gives rise to atrioventricular conduction system. 5 Early retroviral labeling studies demonstrated that CCS and working myocyte lineages shared a common progenitor, 6,7 and that the Purkinje fibers are derived from differentiated ventricular cardiomyocytes. [8] [9] [10] [11] However, questions remain as to lineage origins and the dynamic formation of each component of the CCS during development.
C ardiac arrhythmias are a leading cause of death and are often a result of abnormalities in the specialized cardiac conduction system (CCS). Understanding origins of CCS lineages and identifying markers that can be used for their isolation from human embryonic stem cells or induced pluripotent stem cells are essential steps toward modeling diseases of the CCS, to study drug responses of specific CCS lineages, or to develop biological pacemakers. retrospective clonal analysis in mouse embryos. [12] [13] [14] These lineages are thought to diverge around the onset of gastrulation. 15 The first lineage gives rise to the first heart field, which is defined as the first cells to differentiate in the cardiac crescent. 12, 16 Thus, the first heart field comprises differentiated myocytes that are precursors of distinct myocyte populations within the developing heart. Myocytes of the first heart field give rise to the early heart tube and later give rise to most myocytes of the left ventricle and a subset of myocytes within both atria.
The second lineage gives rise to the second heart field that, in contrast to the first heart field, comprises undifferentiated progenitors. At cardiac crescent stages, second heart field progenitors are localized medial and posterior to the first heart field. Growth of the heart after early heart tube stages occurs by successive addition of differentiating second heart field cells to both poles of the heart. The second heart field will give rise to the right ventricle, outflow tract, and a majority of cells within the left and right atria. Studies of the second heart field have been greatly facilitated by discovery of the transcription factor Isl1 as a marker for progenitors of the second heart field. 17 In contrast, studies of the first heart field have been constrained by lack of a comparable marker.
It has been shown that a posteriormost subset of the second heart field, the posterior heart field, marked by Tbx18Cre contributes to SAN formation. 18, 19 However, contributions of first or second heart fields to each component of the developing CCS have not yet been addressed.
The hyperpolarization-activated nucleotide-gated cation channel HCN4 is a pacemaker channel that is highly expressed in the SAN during development and in the adult. [20] [21] [22] In studying expression of HCN4, we noted that HCN4 was expressed in the first differentiating cells of the cardiac crescent and was expressed transiently throughout the early heart tube, 23 suggesting that HCN4 may act as a potential marker of the first heart field and, additionally, as a marker for pacemaker cells of the heart. In this study, we generated several HCN4-knockin mouse lines, including HCN4CreERT2, and -nuclear (n) lacZ or -H2BGFP. Data from these mouse lines, together with data generated using other mouse models marking distinct cardiac lineages, allowed us to assess contributions of first and second heart field lineages to the CCS. We found that the earliest HCN4 expression marks the first heart field, and that HCN4 is dynamically expressed in distinct differentiated cardiomyocyte precursors at different stages of heart development, including myocyte precursors that give rise to distinct components of the CCS. From late fetal to early adult stages, HCN4 expression marks all components of the CCS. We also noted HCN4 expression in specific subsets of endothelium at distinct times during development. Our data give insight into the activation of HCN4 during development of distinct conduction system precursors, and suggest the use of HCN4 in concert with other markers to isolate specific CCS precursors at distinct stages of development.
Methods

Animals and Tamoxifen Induction
To generate HCN4CreERT2-knockin mouse lines, a SalI DNA cassette containing CreERT2 was inserted immediately before endogenous ATG of HCN4 gene. Two recombinant clones were used for blastocyst injections, and chimeric mice were crossed to C57BL/6J females to generate heterozygous HCN4CreERT2-knockin mice (Online Figure IA) . A similar strategy was used to generate HCN4H2BGFP-and HCN4nLacZ-knockin allele (Online Figure IB and IC).
For lineage analysis, Cre mice were crossed with RosaLacZ, 24 Rosa-tdTomato, 25 or Rosa mT/mG 26 reporter mice, and pregnant female mice at desired times were fed 150 (≤E11.5) to 250 μL (≥E12.5) of tamoxifen (10 mg/mL; Sigma-Aldrich, St. Louis, MO) by oral gavage. Samples were harvested at E16.5 or at desired time points. All the experiments involving mice were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee of USCD, USA (A3033-01) and by the Animal Committee of Tongji University School of Medicine, China (TJmed-010-10).
Immunohistochemistry and Xgal Staining
Immunohistochemistry and Xgal staining were performed as described. 27 Briefly, samples were fixed in 4% paraformaldehyde, embedded, sectioned, and immunostained with antibodies as listed below: rat anti-HCN4 (Abcam), rabbit anti-Cx40 (Santa Cruz, Biotechnology), goat anti-Tbx3 (Santa Cruz, Biotechnology), mouse anti-NKX2.5 (Santa Cruz Biotechnology), rat anti-platelet-endothelial cell adhesion molecule (PECAM)-1 (BD Pharmingen), mouse anti-MF-20 (Developmental Studies Hybridoma Bank), and mouse anti-Troponin T (NeoMarkers, MSZ-295-P). The secondary antibody was Alexa Fluor 488, 594 and 647 conjugated (Invitrogen).
For quantitative assessment, hearts of appropriate developmental stages were cut at 10 μm, every fourth to sixth section was stained, and cells positive for lineage marker (mGFP+) within each defined area of the CCS were counted. Relative contribution of each lineage was expressed as a percentage of total number of HCN4-or Cx40expressing cells within the same CCS area.
For wholemount immunostaining, samples were fixed in 4% paraformaldehyde and dehydrated in gradients of methanol (50%, 70%, and 100%) for 1 hour each. Samples were fixed in methanol/dimethyl sulfoxide (4:1) overnight, then transferred to methanol/dimethyl sulfoxide/H 2 O 2 (4:1:1) at room temperature for 6 hours. Samples were rehydrated and stained at 4ºC with antibody to Isl1 (Developmental Studies Hybridoma Bank) for 48 hours, and then secondary antibody for 24 hours at 4ºC. Samples were washed and incubated in DAB solution (Vector).
Statistical Analyses
Data are presented as mean±SEM, and Student t test was used for 2-group comparisons. For experimental details, see the Online Data Supplement.
Results
Expression of HCN4nLacZ in the First Heart Field and the CCS
To better facilitate visualization of HCN4 expression, we generated mice with CreERT2, or a nuclear localized (n) LacZ or H2BGFP 28 knocked into the endogenous HCN4 locus (Online Figure I) , and analyzed reporter expression in the heart during development.
Consistent with previous RNA in situ data, 23 expression of HCN4nlacZ was first observed in the cardiac crescent at E7.5 ( Figure 1A) , and remained throughout the early heart tube at ≈E8.0 to 8.5 ( Figure 1A-1B′ ). Wholemount immunostaining at E7.5 with antibody to HCN4 revealed expression of HCN4 in the cardiac crescent ( Figure 1C ), consistent with previous RNA in situ analyses 23 and expression of the HCN4nLacZ reporter ( Figure 1A ). Wholemount Xgal staining and coimmunostaining at E7.5 with antibody to Isl1, a marker of the second heart field, revealed that HCN4nLacZ expression was adjacent and lateral to Isl1-expressing second heart field cells ( Figure 1D , arrowhead), suggesting that earliest HCN4 expression marks the first heart field. At E10.5 to E12.5, HCN4nlacZ was highly expressed in some components of the CCS, including SAN, AVN, and left bundle branches; Figure 1E , 1E′, 1G, and 1G′. Interestingly, expression of HCN4nLacZ at these stages was also prominent in left ventricular myocardium and atria, with some expression in a small subset of right ventricular myocardium ( Figure 1E1 , 1E′1, 1G, and 1G′), consistent with HCN4 expression in the first heart field. Because previous RNA in situ had revealed that HCN4 expression at E11.5 to 12.5 is confined to the vena cava, sinoatrial junctions, and coronary sinus, 23 expression of the HCN4nlacZ reporter in left ventricle and atria at this stage is likely to reflect perdurance of the β-galactosidase protein, acting as a lineage tracer. Alternatively, it may be attributable to loss of endogenous negative regulation because of the introduction of heterologous UTRs in the targeting construct. Coimmunostaining with antibodies to HCN4 and Tbx3, a marker of the SAN, revealed HCN4 expression in SAN at E10.5 ( Figure 1F and 1F′).
With further development, expression of HCN4nLacZ was gradually confined to the CCS. At E16.5 ( Figure 1H and 1H′) and in adult heart ( Figure 1I ), the HCN4nlacZ transgene was expressed within all parts of the CCS, including SAN, the crista terminalis, AVN, His-bundle, bundle branches, and Purkinje fibers.
HCN4 Is Expressed in Cardiomyocytes and in Some Endothelial Populations
Expression of HCN4H2BGFP during development was consistent with that of HCN4nLacZ (Online Figure II) . To . HCN4 is expressed in cardiomyocytes, and in some endothelial populations. A, Coexpression of HCN4H2BGFP and myocyte marker mf20 (A) at E9.5. Majority of mf20expressing atrial myocytes and left ventricular (lv) myoctyes coexpress HCN4H2BGFP (A, inset 2). A few HCN4H2BGFP cells were also observed in right ventricular trabeculae around the ventricular septum (vs). Few if any HCN4H2BGFP cells were observed in the free wall of the right ventricle (A, inset 1). B, At E9.5, few if any HCN4H2BGFP cells in the heart express endothelium/endocardial marker pecam (B, inset). C-H, Coexpression of HCN4H2BGFP and mf20 and pecam at E12.5. HCN4H2BGFP is expressed in the endothelial cells of the aorta (ao) and pulmonary artery (pa) that coexpress with pecam (D, inset), but not mf20 (C, inset). Majority of HCN4H2BGFP cells in the left ventricle coexpress mf20 (E, inset), a portion of HCN4H2BGFP cells express pecam (F, inset). HCN4CreERT2 lineage-labeled cells (tdTomato) coexpressed mf20 (G, inset) or but not pecam (H, inset).
examine the cell identity of HCN4-expressing cells within the heart, we performed immunostaining with antibodies to cardiomyocytes (MF20, Troponin T, and Nkx2.5) and endothelial cells (PECAM) and colocalized these markers with HCN4H2BGFP at E9.5 to E12.5 (Figure 2A -2F and not shown). At E9.5, HCN4H2BGFP cells were observed prominently in the left ventricle and atria, with a few GFP cells in right ventricular trabeculae, but not right ventricular wall (Figure 2A , inset 1 and 2). These HCN4H2BGFP cells coexpressed cardiomyocyte markers MF20 (Figure 2A , inset 2), Nkx2.5, and Troponin T (not shown). However, expression of HCN4H2BGFP at this stage did not colocalize with the endothelial marker PECAM ( Figure 2B , inset). At E12.5, HCN4H2BGFP was expressed in endothelial cells of the aorta and pulmonary artery, coexpressed with PECAM ( Figure 2D , inset), but not with MF20 ( Figure 2C , inset). The majority of HCN4H2BGFP cells in left ventricle at E12.5 coexpressed MF20 ( Figure 2E , inset), and a subset of HCN4H2BGFP cells also expressed PECAM ( Figure 2F , inset).
To examine the fate of HCN4-expressing cells, we generated an HCN4 tamoxifen-inducible Cre by knocking CreERT2 into the endogenous HCN4 locus (Online Figure I) . To examine whether the earliest HCN4 lineages contributed to myocardium and endothelium/endocardium, HCN4CreERT2 mice were crossed with Rosa-tdTomato indicator mice, 25 pregnant females were fed with tamoxifen at E7.5, and hearts were analyzed at E12.5 by direct visualization of tdTomato and coimmonstained with MF20 or PECAM antibodies. HCN4CreERT2 lineage-labeled cells (red) were observed in the left ventricle, which coexpressed MF20 ( Figure 2G , inset), but not PECAM ( Figure 2H, inset) .
Together, these studies suggested that earliest HCN4 lineages do not contribute to endocardium, and that HCN4 is de novo expressed in endothelial/endocardial cells at later developmental stages. At later stages of development (E16.5) and adult, we also observed expression of HCN4nLacZ in a subset of endothelial cells of the aorta, pulmonary artery, and coronary arteries, but not in superior vena cava (Online Figure III , data not shown).
Contribution of HCN4 Lineages to First Heart Lineages and the CCS During Development Revealed by HCN4CreERT2 Fate Mapping
To examine further the fate of HCN4-expressing cells during development, HCN4CreERT2 mice were bred into an R26RLacZ reporter background. 24 Tamoxifen inductions were performed at distinct stages of embryonic development, harvesting at E16.5 when the CCS is well defined 29, 30 (Figure 3) .
To analyze the fate of HCN4-expressing myocytes of the first heart field, HCN4CreERT2;R26RLacZ mice were fed Tamoxifen was given to HCN4CreERT2;R26RLacZ pregnant females at distinct developmental stages as indicated, hearts were harvested at E16.5 and stained with Xgal. A-F, Ventral and dorsal view; (A′-F′) serial section. A and A′, A few HCN4 lineage-labeled cells (Xgal+) were found in coronary sinus (cs) and atrioventricular region (arrow) when tamoxifen induction was performed at E6.5. B and B′, Inductions at E7.5 resulted in labeling of cells in left ventricle and trabeculae/Purkinje fibers (pf), left bundle branch (lbb), both atria, coronary sinus (cs), venous valves (vv), and a small number of cells in atrioventricular node (avn). A few labeled cells were also observed in the Crista terminalis (Ct), and distal tail of san. C and C′, Inductions at E8.5 resulted in a similar labeling pattern to that observed at E7.5, except that labeling of cells in san, avn, and His-bundle was markedly increased. D-F′, Inductions at E9.5 (D and D′), E11.5 (E and E′), and E12.5 (F and F′) resulted in selective labeling of cells in san, avn, and coronary sinus. At E9.5, there was some labeling of Purkinje fibers and ventricular and atrial myocytes, which disappeared with later inductions. No significant labeling was observed in His-bundle or bundle branches with inductions at these stages.
with tamoxifen at E6.5 and E7.5. When harvested at E16.5, a few Xgal-labeled cells were observed in the coronary sinus after inductions at E6.5 ( Figure 3A and 3A′ ). Inductions at E7.5 ( Figure 3B and 3B′) resulted in selective labeling of cells within the coronary sinus, SAN tail, venous valves, left bundle branch, Purkinje fibers, left ventricle, ventricular septum, and both atria. Infrequent labeling was also observed of Purkinje fibers within right ventricle, consistent with low levels of HCN4nLacZ/H2BGFP observed at E10.5 and E12.5 within the right ventricular trabeculae. Inductions at E8.5 ( Figure 3C and 3C′) labeled the foregoing populations and, in addition, the SAN head, AVN, His-bundle, and atrial septum. Inductions at E9.5 ( Figure 3D and 3D′) resulted in labeling of more restricted cell populations than at E8.5, with reduced labeling of Purkinje fibers, left ventricle, and atria, and strong labeling of the SAN, AVN, atrial septum, left superior vena cava, and the coronary sinus. Inductions at E11.5 to E12.5 resulted in labeling of SAN, AVN, left superior vena cava, and the coronary sinus, with few or no cells labeled in left ventricle ( Figure 3E , 3E′, 3F, and 3F′).
Contribution of HCN4 Lineages to Components of the Forming CCS
To confirm that HCN4CreERT2 lineages were giving rise to cells of the CCS, inductions were also performed in an HCN4CreERT2;Rosa-mT/mG indicator background 26 to facilitate coimmunostaining with markers of the CCS. HCN4 was used to label SAN, AVN, and His-bundle, and Cx40 was used to label bundle branches and Purkinje fibers (Figure 4 ). Inductions were performed at multiple stages, harvesting at E16.5, as previously, and gave results consistent with those with the R26RLacZ reporter.
Tamoxifen induction at E7.5 resulted in labeling of cells (mGFP) in a subset of cells in SAN, venous valves, and AVN as seen by colocalization with endogenous HCN4 (Figure 4A-4B′ ). HCN4CreERT2 lineage-labeled cells were also found in left bundle branch and Purkinje fibers as seen by colocalization with Cx40 ( Figure 4C-4D′) . A subset of myocytes in atria ( Figure 4A ) and left ventricle ( Figure 4D ) that do not actively express HCN4 at E16.5 were also labeled.
Induction at E9.5 resulted in increased labeling of cells in SAN and AVN as marked by HCN4 ( Figure 4E-4F′) , and labeling of left bundle branch and Purkinje fibers marked by Cx40 ( Figure 4G-4H′ ). Similar to inductions at E7.5, no HCN4CreERT2 lineage-labeled cells were found in right bundle branch and His-bundle ( Figure 4F , not shown).
Inductions at E12.5 resulted in labeling of cells in SAN, AVN, venous valves, and a few cells in His-bundle ( Figure 4I-4J′ ), but no labeled cells were observed in left bundle branch or Purkinje fibers ( Figure 4K-4L′ ). However, inductions performed at E16.5, harvesting at postnatal day Tamoxifen was given to HCN4CreERT2;Rosa mT/mG pregnant females at distinct developmental stages as indicated. Hearts were harvested at stages indicated, and sections coimmunostained with antibody to HCN4 as a marker for sinoatrial node (san), atrioventricular node (avn), and His-bundle (hb); and Cx40 as marker for His-bundle and Purkinje fibers (pf; A′-P′). A-D′, Tamoxifen induction at E7.5 resulted in labeling of cells (mGFP) in san, venous valves (vv; A), and avn (B) as seen by colocalization with endogenous HCN4 (A′ and B′). HCN4CreERT2 lineage-labeled cells were also found in left bundle branch (lbb; C) and Purkinje fibers (D) as seen by colocalization with Cx40 (C′ and D′), and a subset of cells in atria (A) and left ventricle (D) that do not actively express HCN4 at E16.5. E-H′, Induction at E9.5 resulted in labeling of cells in san, venous valves (A), and avn as marked by HCN4 (E′ and F′), and left bundle branch and Purkinje fibers marked by Cx40 (G′ and H′). Similar to induction at E7.5, no HCN4CreERT2 lineage-labeled cells were found in right bundle branch or His-bundle (F, not shown). I-L′, Inductions at E12.5 resulted in labeling of cells in san, avn, and venous valves. A few labeled cells were found in His-bundle (J), but no HCN4CreERT2 lineage-labeled cells were observed in left bundle branch (K) or Purkinje fibers (L). M-P′, Inductions at E16.5 and harvested at postnatal day 1 (P1) resulted in labeling of cells in all components of the CCS, including san, avn, and His-bundle, as marked by HCN4 (M-N′), right and left bundle branch (N-O′) and Purkinje fibers as marked by Cx40 (P and P′). Figure 4M -4P′), resulted in labeling of all components of the CCS, including those not labeled by inductions at E12.5, the His-bundle, bundle branch, and Purkinje fibers ( Figure 4N-4P′) , demonstrating re-expression or de novo expression of HCN4 in distinct components of the CCS at later stages.
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Contribution of the First and Second Heart Fields to Components of the CCS
These data suggested that the earliest expression of HCN4 in the cardiac crescent and early heart tube labeled the first heart field because HCN4 lineages were largely excluded from second heart field-derived outflow tract and right ventricle. To investigate further the contribution of first and second heart lineages to the CCS, we performed lineage tracing experiments using several Cre mouse lines. Nkx2.5Cre 31 labels the first and second heart fields, Isl1Cre labels the second heart field, 17 and Tbx18Cre labels a posteriormost subset of the second heart field, which will contribute to the SAN. 18, 19, 32 Each of these Cre was bred into the Rosa-mT/mG indicator background, 26 and coimmunostainings were performed at E16.5 using Tbx3 to label SAN, AVN, and His-bundle ( Figure 5A′-5I′) , and Cx40 to label bundle branches and Purkinje fibers ( Figure 5J′-5M′) .
A majority of cells in AVN, His-bundle, left bundle branch, and Purkinje fibers were labeled by Nkx2.5Cre ( Figure 5D , 5G, 5J, and 5L), whereas only a small subset of Nkx2.5Crelabeled cells were found at the boundary of the SAN and right atria ( Figure 5A′) . In contrast, a majority of SAN cells were found to be Isl1Cre and Tbx18Cre labeled ( Figure 5B and 5C), whereas only a small subset of AVN and His-bundle cells were labeled by Isl1Cre, but not by Tbx18Cre ( Figure 5E , 5F, 5H, and 5I). A majority of cells in right bundle branches, and a substantial number of Purkinje fibers in the right ventricle were also labeled by Isl1Cre ( Figure 5K and 5M) .
Quantitative assessment of the contribution of each lineage to distinct components of the CCS was performed (Table) . Results of these analyses were consistent with lineage data generated by early inductions (E6.5-E8.5) of HCN4CreERT2 ( Figure 3A-3C ). Consistent with their derivation from the first heart field, a majority of cells within the AVN (98±1.1%), His-bundle (91.4±3.5%), left bundle branch (89.8±2.5%), and Purkinje fibers were selectively labeled by Nkx2.5Cre (Table; Figure 5D , 5G, 5J, and 5L), but not Isl1Cre (Figure 5E, 5H , 5K, and 5M).
Nkx2.5Cre lineages contributed to a small subset of cells within the SAN tail (9.4±3.2%; Figure 5A ), consistent with Figure 5B and 5C), consistent with inductions of HCN4CreERT2 at E8.5 ( Figure 3C ), suggesting that, in addition to marking the first heart lineage selectively at earliest stages, by E8.5 HCN4 is also expressed in the posterior second heart field, overlapping with Isl1 in SAN precursors.
A majority of cells in the right bundle branch (90.5±3.8%) was labeled by Isl1Cre (Table; Figure 5M ), but was not labeled by HCN4CreERT2 at early stages (Figure 3 ), confirming derivation from the second heart field. Purkinje fibers within the right ventricle arise both from second heart field and first heart field, as indicated by labeling of a subset of these cells by Isl1Cre (59±1.9%) and a subset by Nkx2.5Cre (88±2.2%), respectively (Table; Figure 5L and 5M).
Altogether, our data suggest a model for lineage derivation and timing of differentiation of CCS precursors in developing heart, as summarized in Figure 5N . Precursors to left Purkinje fibers, left bundle branch, and a subset of right Purkinje fibers were among first heart field myocytes marked by HCN4CreERT2 inductions at E7.5 (cardiac crescent; blue). The foregoing CCS lineages and precursors to the Hisbundle and AVN were marked by slightly later inductions of HCN4CreERT2 at E8.5 (early heart tube; purple). With the exception of a majority of right Purkinje fibers, which were marked by Isl1Cre (orange), these CCS lineages were not marked by Isl1Cre, consistent with their being derived from the first heart field. Inductions of HCN4CreERT2 at E8.5 also marked SAN precursors, as did Isl1Cre, indicating derivation of most SAN cells from the second heart field (pink), and reflecting expression of HCN4 in SAN precursors. The right bundle branch was also derived from the second heart field, being exclusively marked by Isl1Cre (orange). A very few precursors to the SAN and AVN were labeled by inductions of HCN4CreERT2 at E7.5 (blue).
Discussion
The hyperpolarization-activated nucleotide-gated cation channel HCN4 has been described as a marker of the pacemaker of the heart, the SAN, both during early and later development. [20] [21] [22] We observed that HCN4 was expressed in the first differentiating cells of the cardiac crescent, and was expressed transiently throughout the early heart tube. 23 These observations suggested that HCN4, in addition to being a marker for pacemaker cells of the heart, might be a marker of the first heart field. To explore the significance further of the dynamic expression of HCN4 during heart development and its relationship to CCS development, we generated a number of HCN4-knockin mouse lines.
Analyses with these mice, complemented by studies with other cardiac lineage-restricted Cre mice (Isl1Cre, Nkx2.5Cre, and Tbx18Cre), demonstrated that earliest expression of HCN4 marks the first heart field, in an expression domain complementary to that of Isl1. At this stage, and at later embryonic stages, HCN4 expression dynamically marks differentiated myocyte precursors of distinct components of the CCS. These precursors include those that will give rise both to working myocytes and those of the specialized conduction system, as demonstrated in previous studies. [6] [7] [8] [9] [10] [11] At late fetal stages (E16.5), HCN4 specifically marks all components of the CCS, being reactivated in some populations with a previous history of HCN4 expression, and activated de novo in others. These observations speak to a complex regulation of HCN4 expression during development, and it will be of great interest to investigate transcriptional regulatory mechanisms underlying this dynamic expression pattern.
Our data have given new insights into lineage origins of the CCS, and the order in which distinct precursors for each component express HCN4 and are allocated to the CCS ( Figure 5N ). The earliest HCN4-expressing cells of the first heart field contribute a few cells to the SAN tail, but later HCN4-expressing cells from the posterior second heart field contribute a majority of cells to the SAN (Figure 5N, pink) . HCN4 is expressed very early in precursors of the left and a subset of right Purkinje fibers and left bundle branch ( Figure 5N, blue) , and slightly later also marks precursors of the His-bundle ( Figure 5N, purple) , but expression within these cell populations themselves is downregulated by E11.5, with HCN4 expression remaining on only in components of the central CCS, SAN, and AVN. Previous studies using a Tbx2Cre allele, which demonstrated that atrioventricular canal myocardium participates in formation of the AVN, but not of the His-bundle and bundle branches, indicate that AVN and His-bundle do not develop from a common progenitor population, but segregate early in development. 5 Our data suggest that left bundle branch precursors differentiate before precursors of the AVN and His-bundle ( Figure 5N, blue and purple) . The lineage relationship between trabecular myocardium and the Purkinje fiber network has been reaffirmed using an inducible Cx40Cre, which demonstrated that early trabeculae will give rise to both Purkinje fibers and working myocytes, 6,33 consistent with our observations of HCN4CreERT2 labeling both lineages. By E16.5 through adult stages, HCN4 is expressed throughout the CCS, suggesting reactivation in most components of the ventricular conduction system, and de novo activation in right bundle branch, which was not significantly marked by earlier inductions of HCN4CreERT2 ( Figure 5N , orange and blue).
Our data highlight the use of HCN4 as a marker for precursors of the CCS and emphasize that HCN4 expression marks distinct precursors or components of the CCS at distinct times during development. Our data suggest the use of HCN4 in conjunction with other markers to optimize protocols for the generation of specific conduction system precursors. In this context, it is also important to note that we have also observed HCN4 expression in several endothelial populations at distinct stages of development, including endothelium of the aorta and pulmonary artery, some coronary vessel endothelium, and a subset of endocardial cells (Figure 2 ; Online Figure III) .
The HCN4-knockin mouse lines that we have generated should be of use for future studies on HCN4 lineages. Although we have not observed any baseline electrophysiological phenotypes in mice that are heterozygous for HCN4, in keeping with the published literature, 34 heterozygosity of HCN4 should be kept in mind as a potential complicating factor when using these mice, particularly in the case of ablation of other genes important for conduction system function, in light of potential genetic interactions. In experiments with HCN4CreERT2, our controls included mice both with and without tamoxifen treatment, and we did not observe leaky activity of the Cre. However, this must be kept in mind as a possibility when using these mice.
Conclusion
In summary, these studies have demonstrated that earliest expression of HCN4 specifically marks the first heart field, permitting early inductions of HCN4CreERT2 to shed light on cell fates adopted by the first heart field. Dynamic expression of HCN4, in concert with other lineage specific Cres, has allowed us to examine the temporal recruitment of CCS lineages, and their lineage origins, giving new insight into formation of the CCS. Additionally, our data highlight the potential of HCN4 in concert with other markers in identifying distinct CCS precursor populations, both in mouse embryos and potentially in embryonic stem cells or other pluripotent stem cells.
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